xevinapant
Merck and Debiopharm agree €898m deal to develop head and neck cancer treatments
March 1, 2021Sales and Marketing Debiopharm, Merck, cancer treatment, head and neck cancer, xevinapant
German science and technology company Merck have agreed a worldwide in-licensing agreement with Debiopharm for the development and commercialisation of …
Latest content
Highlighting the value of lab research for healthcare innovation
November 2, 2026
Medtronic secures CE Mark for new cardiac pacing portfolio
October 30, 2026
Dermatology leader Doncker is new Onicor CEO
October 29, 2026
